Daiichi Sankyo ENHERTU gets Japanese nod for patients with previously treated HER2 Positive Metastatic Breast Cancer Ruchika Sharma25 Nov 2022 1:30 PM ISTENHERTU (trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC.
AstraZeneca- Daiichi Sankyo Enhertu recommended for nod in EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer Ruchika Sharma15 Nov 2022 12:15 PM ISTEnhertu is a HER2-directed ADC.
California Court orders in favor of Plexxikon in dispute with Novartis Ruchika Sharma4 Oct 2022 6:00 PM ISTTokyo: Daiichi Sankyo has announced that the U.S. District Court for the Northern District of California has issued an order sustaining a jury...
IHH Healthcare in talks with Indian authorities over stalled open offer for additional 26.1 percent stake in Fortis Healthcare Ruchika Sharma28 Sept 2022 4:15 PM ISTIt further said that the order by the apex court "supports our belief that our investment into Fortis was undertaken in a fair and transparent...
6 months jail to Singh brothers In Daiichi-Fortis Case, SC refuses to lift stay on Fortis-IHH open offer Farhat Nasim22 Sept 2022 2:41 PM ISTNew Delhi: The former promoters of Fortis Healthcare, Malvinder Singh and Shivinder Singh (Singh brothers) will now have to serve a jail term of 6...
Thermo Fisher Scientific secures USFDA nod for Oncomine Dx Target Test for lung cancers with HER2 mutations Ruchika Sharma15 Aug 2022 12:00 PM ISTThe Oncomine Dx Target Test is designed to simultaneously evaluate 23 genes associated with NSCLC.
AstraZeneca, Daiichi Sankyo get USFDA accelerated nod for Enhertu for HER2 Mutant Non-small Cell Lung Cancer Ruchika Sharma14 Aug 2022 3:30 PM ISTEnhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi...
AstraZeneca Enhertu secures USFDA nod for HER2-low breast cancer Ruchika Sharma6 Aug 2022 2:30 PM ISTEnhertu is a HER2-directed ADC.
AstraZeneca, Daiichi Sankyo get USFDA nod for Enhertu for earlier breast cancer use Ruchika Sharma6 May 2022 5:08 PM ISTThe approval was granted under the FDA's Real-Time Oncology Review (RTOR) programme and converts the accelerated approval of Enhertu in later line...
Daiichi Sankyo gets Japenese nod for Tarlige tablets to treat neuropathic pain Ruchika Sharma31 March 2022 9:45 AM ISTTokyo: Daiichi Sankyo Company, Limited has announced that the company has obtained approval in Japan to change the indication of the analgesic...
US Fund Emqore sues Fortis parent IHH for USD 6.5 billion Medical Dialogues Bureau11 Jan 2022 3:22 PM ISTNew Delhi: In a stock exchange filing last week, Malaysian healthcare group IHH Healthcare Berhad (IHH) said that US fund Emqore Envesecure Private...
Daiichi Sankyo submits NDA for Lymphoma treatment Valemetostat in Japan Ananya Shrivastava2 Jan 2022 10:45 AM ISTTokyo: Daiichi Sankyo Company, Limited has announced that it has submitted a New Drug Application (NDA) to Japan's Ministry of Health, Labour and...
